REGN2477+REGN1033
R2477-1033-sIBM-1828
Phase 2 small_molecule terminated
Quick answer
REGN2477+REGN1033 for Sporadic Inclusion Body Myositis is a Phase 2 program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- REGENERON PHARMACEUTICALS, INC.
- Indication
- Sporadic Inclusion Body Myositis
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated